JAK1 and neoplasm: Recent studies have identified JAK1 as an oncogenic driver in various lymphomas, particularly in relapsed or refractory peripheral T-cell lymphoma (PTCL), where its sustained activation is associated with enhanced tumor proliferation, survival, migration, and suppression of anti-tumor immunity (189).